FLT3 and acute myeloid leukemia: The FLT3 mutation rates were found to be 14.4% for ALL and 32.3% for AML, indicating an increase compared to previous studies [5,6], demonstrating the superior sensitivity and enhanced detection capabilities of NGS [25,26].